98%
921
2 minutes
20
This work addresses the establishment and characterization of gellan gum:pectin (GG:P) biodegradable mucoadhesive beads intended for the colon-targeted delivery of resveratrol (RES). The impact of the polymer carrier system on the cytotoxicity and permeability of RES was evaluated. Beads of circular shape (circularity index of 0.81) with an average diameter of 914 μm, Span index of 0.29, and RES entrapment efficiency of 76% were developed. In vitro drug release demonstrated that beads were able to reduce release rates in gastric media and control release for up to 48 h at an intestinal pH of 6.8. Weibull's model correlated better with release data and parameter (0.79) indicated that the release process was driven by a combination of Fickian diffusion and Case II transport, indicating that both diffusion and swelling/polymer chains relaxation are processes that contribute equally to control drug release rates. Beads and isolated polymers were observed to be safe for Caco-2 and HT29-MTX intestinal cell lines. RES encapsulation into the beads allowed for an expressive reduction of drug permeation in an in vitro triple intestinal model. This feature, associated with low RES release rates in acidic media, can favor targeted drug delivery from the beads in the colon, a promising behavior to improve the local activity of RES.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414934 | PMC |
http://dx.doi.org/10.3390/polym10010050 | DOI Listing |
Blood
September 2025
University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic.
Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).
View Article and Find Full Text PDFClin Cancer Res
September 2025
University of Southampton, Southampton, United Kingdom.
Purpose: Varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e.
View Article and Find Full Text PDFESC Heart Fail
September 2025
Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong.
Aims: Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse-coordinated multidisciplinary comprehensive HF management programme on HF patients.
Methods And Results: This retrospective cohort study involved patients admitted for acute HF exacerbation at a regional hospital in Hong Kong.
Oper Neurosurg
September 2025
Department of Neurosurgery and the Training Base of Neuroendoscopic Physicians under the Chinese Medical Doctor Association, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.
Background And Objectives: Microvascular decompression (MVD) for hemifacial spasm (HFS) is commonly conducted under a microscope. We report a large series of fully endoscopic MVDs for HFS and describe our initial experience with 3-dimensional (3D) endoscopy.
Methods: Clinical data of 204 patients with HFS who underwent fully endoscopic MVD using 2-dimensional (2D) and 3D endoscopy (191 and 13 patients, respectively) from July 2017 to October 2024 were retrospectively analyzed.
Malignant phyllodes tumors of the breast are rare fibroepithelial neoplasms with aggressive behavior and high recurrence rates. They pose significant diagnostic and therapeutic challenges due to their overlap with other malignancies, necessitating accurate diagnosis and a tailored treatment approach to improve patient outcomes. A 29-year-old Asian female initially underwent a lumpectomy for a right breast mass diagnosed as a phyllodes tumor on histopathology.
View Article and Find Full Text PDF